Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590

Heather A. Wakelee, Patricia Stephenson, Steven M. Keller, Henry Wagner, Arnold Herskovic, Ritsuko Komaki, Randolph S. Marks, Michael C. Perry, Robert B. Livingston, David H. Johnson

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Fingerprint

Dive into the research topics of 'Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590'. Together they form a unique fingerprint.

Medicine & Life Sciences